Apogee Therapeutics, Inc. Common Stock (APGE)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$135.07

+0.00 (+0.00%)

Market Cap: $10.22B

Last updated: Sep 04, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

38%(5/13)

Avg Surprise

-20.82%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-1.25

Range$-1.27 - $-1.23

2 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-1.17-7.1%

60d ago$-1.16-8.2%

30d ago$-1.16-8.2%

7d ago$-1.19-5.0%

Current$-1.25

Revenue Consensus

Range$0 - $0

6 analysts

Period ending Dec 31, 2026

EPS Consensus$-1.52

Range$-1.59 - $-1.45

2 analysts

Revenue Consensus

$-10000000

Range$-10000000 - $-10000000

6 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.52	$-1.59 - $-1.45	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-1.25	$-1.27 - $-1.23	-	-	2	2 3 30d	-
Jun 30, 2026Jun 26 Reported Aug 10, 2026Reported Aug 10	$-1.14	$-1.10	$-1.25 - $0.31	-3.64%	Miss	11	2 1 30d	-0.9%
Mar 31, 2026Mar 26 Reported May 11, 2026Reported May 11	$-1.06	$-1.13	$-1.22 - $-0.99	+6.19%	Beat	12	1 1 30d	-11.6%
Dec 31, 2025Dec 25 Reported Mar 2, 2026Reported Mar 2	$-1.03	$-0.62	$-0.75 - $-0.45	-66.13%	Miss	10	2 0 30d	+12.7%
Sep 30, 2025Sep 25 Reported Nov 10, 2025Reported Nov 10	$-1.11	$-1.15	$-1.32 - $-1.02	+3.48%	Beat	6	No revisions (30d)	-29.1%
Jun 30, 2025Jun 25 Reported Aug 11, 2025Reported Aug 11	$-1.13	$-1.05	$-1.11 - $-0.97	-7.62%	Miss	4	1 0 30d	-88.3%
Mar 31, 2025Mar 25 Reported May 12, 2025Reported May 12	$-0.95	$-1.19	$-1.21 - $-1.16	+20.17%	Beat	4	No revisions (30d)	-48.4%
Dec 31, 2024Dec 24 Reported Mar 3, 2025Reported Mar 3	$-1.18	$-0.62	$-0.83 - $-0.46	-90.32%	Miss	4	0 2 30d	-268.7%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.86	$-0.74	$-1.05 - $-0.63	-16.22%	Miss	6	No revisions (30d)	-68.6%
Jun 30, 2024Jun 24 Reported Aug 12, 2024Reported Aug 12	$-0.60	$-0.55	$-0.70 - $-0.53	-9.09%	Miss	6	No revisions (30d)	+84.1%
Mar 31, 2024Mar 24 Reported May 13, 2024Reported May 13	$-0.64	$-0.65	$-0.75 - $-0.46	+1.54%	Beat	4	No revisions (30d)	+73.1%
Dec 31, 2023Dec 23 Reported Mar 5, 2024Reported Mar 5	$-0.32	$-0.49	$-0.59 - $-0.44	+34.69%	Beat	5	No revisions (30d)	-
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-0.51	$-0.42	-	-21.43%	Miss	-	-	-
Jun 30, 2023Jun 23 Reported Jul 17, 2023Reported Jul 17	$-3.78	$-1.70	-	-122.35%	Miss	-	-	-
Mar 31, 2023Mar 23 Reported May 31, 2023Reported May 31	$-2.38	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-32.50%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	0.33	Avg Volume	N/A
52-Week High	$135.09	52-Week Low	$35.39

Technical Indicators Dashboard

Moving Averages

SMA 10$134.99

SMA 20$134.81

SMA 50$134.22

SMA 200$92.67

EMA 10$134.98

EMA 20$134.59

EMA 50$128.59

EMA 200$97.15

MACD

Line: 0.99Signal: 1.34Hist: -0.35

ADX

ADX: 65.8+DI: 44.6-DI: 8.5

Aroon & PSAR

Aroon Up92.0

Aroon Down4.0

PSAR$134.69

Bollinger Bands

Upper Band$135.23

Lower Band$134.39

%B Position63%(Middle)

Band Width0.81

RSI (14-Day)

Overbought

78.7

Momentum Oscillators

Stoch %K96.6

Stoch %D97.5

Williams %R-3.6

ROC (10d)0.2%

Momentum0.32

CCI (20d)101.0

MFI (14d)93.5

Volatility Measures

ATR (14d)$0.28(0.2%)

StdDev (20d)0.21

Hist Vol1.0%(Low)

Volume Flow

VWAP$135.07

OBV87.9M

AD Line-52.7M

CMF (20d)0.169

Volume Metrics

Avg Vol (20d)1.3M

Vol RatioN/A

VWMA (20d)$134.83

Pivot Points

R3$135.07

R2$135.07

R1$135.07

Pivot Point$135.07

S1$135.07

S2$135.07

S3$135.07

Advanced Oscillators

TSI56.89

Ultimate Osc74.9

KST5.51

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$130,000	$0	$0	$0	$0	$0
Cost of Revenue	$0	$0	$-400,000	$0	$0	$0	N/A	$0	$0	$0	N/A	$0
Gross Profit	$0	$0	$400,000	$0	$0	$0	$65,000	$0	$0	$0	N/A	$0

Operating Expenses	$96.00M	$82.77M	$78.06M	$71.28M	$73.17M	$63.10M	$75.88M	$58.69M	$44.12M	$38.18M	$37.16M	$24.30M
R&D	$67.30M	$60.82M	$58.44M	$54.18M	$55.70M	$46.39M	$60.23M	$45.71M	$33.21M	$28.72M	$28.95M	$17.07M
SG&A	$24.34M	$21.95M	$19.61M	$17.10M	$17.46M	$16.71M	$15.65M	$12.97M	$10.92M	$9.46M	$8.20M	$7.24M
Operating Income	$-96,004,000	$-82,772,000	$-78,056,000	$-71,278,000	$-73,165,000	$-63,096,000	$-75,881,000	$-58,686,000	$-44,122,000	$-38,181,000	$-37,155,000	$-24,305,000

Interest Income	$11.81M	$8.74M	$8.73M	$6.32M	$7.14M	$7.84M	$8.68M	$9.67M	$10.31M	$6.09M	$5.42M	$3.46M
Interest Expense	$1.58M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-85,776,000	$-74,032,000	$-69,325,000	$-64,960,000	$-66,024,000	$-55,256,000	$-67,200,000	$-49,018,000	$-33,816,000	$-32,094,000	$-31,735,000	$-20,840,000
Income Tax Expense	$78,000	$79,000	$62,000	$61,000	$72,000	$83,000	$18,000	$0	$0	$0	$0	$0

Net Income	$-85,854,000	$-74,111,000	$-69,387,000	$-65,021,000	$-66,096,000	$-55,339,000	$-67,218,000	$-49,018,000	$-33,816,000	$-32,094,000	$-31,735,000	$-20,840,000

EBITDA	$-97,336,000	$-83,913,000	$-79,392,000	$-72,492,000	$-74,526,000	$-65,268,000	$-78,791,000	$-62,143,000	$-47,126,000	$-40,862,000	$-39,994,000	$-24,537,000
EBIT	$-96,004,000	$-82,772,000	$-78,056,000	$-71,278,000	$-73,165,000	$-63,096,000	$-75,881,000	$-58,686,000	$-44,122,000	$-38,181,000	$-37,155,000	$-24,305,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about APGE

News

Apogee Therapeutics, Inc.(NasdaqGM: APGE) dropped from S&P TMI Index

Apogee Therapeutics, Inc. (NasdaqGM:APGE) has been dropped from the S&P TMI Index as of September 2, 2026, at 08:22 pm EDT. This news follows several other announcements on September 1, 2026...

marketscreener.com•Sep 2, 2026 4:22 PM ET9/2/26•Bearish

Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry Index

Apogee Therapeutics, Inc. (NasdaqGM:APGE) has been removed from the S&P Biotechnology Select Industry Index, as well as several other S&P and NASDAQ indices...

marketscreener.com•Sep 2, 2026 4:22 AM ET9/2/26•Bearish

AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition

AbbVie Inc. has completed an $8.0 billion senior notes offering to partially fund its acquisition of Apogee Therapeutics...

Investing.com•Aug 18, 2026 5:10 PM ET8/18/26•Neutral

NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE

NINE MASTS CAPITAL Ltd recently acquired a new position of 9,400 shares in Apogee Therapeutics Inc. (NASDAQ:APGE)...

MarketBeat•Aug 18, 2026 6:12 AM ET8/18/26•Neutral

Apogee Therapeutics CMO Dambkowski sells $737k in stock

Carl Dambkowski, CMO of Apogee Therapeutics, sold 5,500 shares for $737,934 on August 5, 2026, under a pre-arranged trading plan...

Investing.com•Aug 17, 2026 2:41 PM ET8/17/26•Neutral

APGE Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -32.5%

APGE Competitors

Company	Ticker
Globus Medical	GMED
The Ensign Group Inc	ENSG
Align Technology Inc	ALGN
Twist Bioscience Corp	TWST
Madrigal Pharmaceuticals Inc	MDGL
Bio-Rad Laboratories Inc	BIO-B
Immunitybio Inc	IBRX
Nuvalent Inc	NUVL

Sector: Healthcare

APGE Analyst Ratings

Consensus: Hold
Analysts: 15
Strong Buy: 0
Buy: 1
Hold: 14
Sell: 0
Strong Sell: 0

APGE Bull Case vs Bear Case

Bear case

APGE beat EPS estimates in 37.5% of its last 8 reported quarters.

APGE Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -19.3%
EPS estimate (fiscal period ending Sep 30, 2026): $-1.25
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 2 up, 3 down

Frequently Asked Questions About APGE

Does APGE pay dividends?

Apogee Therapeutics, Inc. Common Stock (APGE) does not currently pay a regular dividend.

What is APGE's market cap?

Apogee Therapeutics, Inc. Common Stock (APGE) has a market capitalization of $10.22B with a current stock price of $135.07.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In